Zacks Rating on Array BioPharma (ARRY)

Array BioPharma (ARRY) : 7 brokerage houses believe that Array BioPharma (ARRY) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 7 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Array BioPharma (ARRY) : The highest short term price target forecast on Array BioPharma (ARRY) is $13 and the lowest target price is $6. A total of 6 equity analysts are currently covering the company. The average price of all the analysts is $8.17 with a standard deviation of $2.64.


Array BioPharma Inc. has lost 3.7% in the last five trading days and dropped 8.4% in the last 4 weeks. Array BioPharma Inc. is up 3.05% in the last 3-month period. Year-to-Date the stock performance stands at -19.91%. Array BioPharma (NASDAQ:ARRY): On Tuesdays trading session , Opening price of the stock was $3.46 with an intraday high of $3.49. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.38. However, the stock managed to close at $3.38, a loss of 2.03% for the day. On the previous day, the stock had closed at $3.45. The total traded volume of the day was 1,590,035 shares.

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.